Daiichi Sankyo Antibody Drug Conjugate Platform Has Created Its First Winner in Enhertu

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long history, it also has numerous lucrative business lines including generics, anticoagulants, painkillers, and heart medications. In 2019 it formed a partnership with AstraZeneca to co-develop and co-commercialize Enhertu and Dato-DXd, its two leading assets from its ADC platform. We expect its ADC platform and other pipeline assets to drive growth over the next 10 years.